Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Raises $18.2M in Private Stock Sale

NEW YORK (GenomeWeb News) – Fluidigm has raised $18.2 million through the private placement of an undisclosed number of shares, according to a filing with the US Securities and Exchange Commission.

The South San Francisco, Calif.-based firm is seeking to raise up to a total of $24.1 million from the offering, according to the SEC filing.

A Fluidigm spokesman confirmed the amount of money raised so far, but he could not provide any further details at this time.

Fluidigm President and CEO Gajus Worthington recently told GenomeWeb Daily News that the company intends to quadruple the size of its US sales staff to 60 people over the next two years. "It's clear that the market is there, the business is there, and now we really need to hire a large number of experienced sales operations folks in North America," he told GWDN.

The company had planned to go public last year, but was thwarted by the economic downturn and the stock market's nosedive in the fall of 2008. At the time, it had hoped to raise as much as $82 million to support its R&D and commercialization efforts.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.